The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as standard-risk/medium-risk (MR)/high-risk (HR) and those with T-ALL as non-High/HR. PEG-ASNase was administered intravenously at 2500 IU/sqm/dose. All patients received 2 PEG-ASNase doses in induction; thereafter non-HR versus HR patients received 1 versus 6 PEG-ASNase doses, respectively. After the single regular dose of PEG-ASNase at the beginning of delayed intensification, BCP-ALL-MR patients were randomized to receive 9 additional PEG-ASNase doses every 2 weeks (experimental arm [EA]) versus none (standard arm [SA]); HR patients were randomized to receive, in consolidation, 4 weekly PEG-ASNase doses (EA) versus none (SA). The HSR cumulative incidence (CI) was estimated adjusting for competing risks. An HSR occurred in 472 of 6136 (7.7%) patients. T-non- HR/BCP-Standard-Risk, BCP-MR-SA, BCP-MR-EA, HR-SA and HR-EA patients had 1-year-CI-HSR (±SE) rates of 5.2% (0.5), 5.2% (0.5), 4.0% (0.8), 20.2% (1.2), and 6.4% (1.3), respectively. The randomized intensification of PEG-ASNase did not significantly impact on HSR incidence in BCP-MR patients (1-y-CI-HSR 3.8% [0.8] versus 3.2% [0.6] in MR-EA versus MR-SA; P = 0.55), while impacted significantly in HR patients (1-y-CI-HSR 6.4% [1.3] versus 17.9% [1.8] in HR-EA and HR-SA, respectively; P < 0.001). The CI-HSR was comparable among non-HR groups and was not increased by a substantial intensification of PEG-ASNase in the BCP-MR-EA group whilst it was markedly higher in HR-SA than in HR-EA patients, suggesting that, in such a chemotherapy context, a continuous exposure to PEG-ASNase reduces the risk of developing an HSR.

Bicocca Center of Bioinformatics Biostatistics and Bioimaging School of Medicine and Surgery University of Milan Bicocca Monza Italy

Cancer Centre for Children Sydney Children's Hospital Network Westmead NSW Australia

Department of Onco Hematology and Cell and Gene Therapy Bambino Gesù Children's Hospital IRCCS Rome Italy

Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Laboratory of Cancer Pharmacology Milano Italy

Department of Pediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Pediatric Hematology and Oncology Charité and Rudolf Virchow Hospital Berlin Germany

Department of Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Austria

Department of Pediatric Hematology and Oncology University Childrens' Hospital of Münster Germany

Department of Pediatric Hematology Oncology Hannover Medical School Hannover Germany

Department of Pediatrics 1 Pediatric Hematology Oncology ALL BFM Study Group Christian Albrechts University Kiel and University Hospital Schleswig Holstein Campus Kiel Germany

Department of Pediatrics IRCCS San Gerardo dei Tintori Foundation Monza Italy; Department of Medicine and Surgery University of MIlano Bicocca Milano Italy

Pediatric Hematology Oncology Schneider Children's Medical Center Petah Tikva and Sackler Faculty of Medicine Tel Aviv University Petah Tikva Israel

St Anna Children's Cancer Research Institute Vienna Austria

University Children's Hospital Zurich Switzerland

Zobrazit více v PubMed

Pui CH, Campana D, Pei D, et al. . Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360:2730–2741. PubMed PMC

Rizzari C, Conter V, Stary J, et al. . Optimizing Asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25(suppl 1):S1–S9. PubMed

Avramis VI, Sencer S, Periclou AP, et al. . A randomized comparison of native Escherichia coli Asparaginase and polyethylene glycol conjugated Asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood. 2002;99:1986–1994. PubMed

Pieters R, Hunger SP, Boos J, et al. . Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia Asparaginase. Cancer. 2011;117:238–249. PubMed PMC

Muller HJ, Boos J. Use of L- Asparaginase in childhood ALL. Crit Rev Oncol Hematol. 1998;28:97–113. PubMed

Gentili D, Conter V, Rizzari C, et al. . L- Asparaginase depletion in serum and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposure to Erwinia L-Asparaginase. Ann Oncol. 1996;7:725–730. PubMed

Silverman LB, Gelber RD, Dalton VK, et al. . Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211–1218. PubMed

Vrooman LM1, Stevenson KE, Supko JG, et al. . Postinduction dexamethasone and individualized dosing of Escherichia Coli L-Asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013;31:1202. PubMed PMC

Panosyan EH1, Seibel NL, Martin-Aragon S, et al. . Asparaginase antibody and Asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004;4:217. PubMed

Gupta S, Wang C, Raetz EA, et al. . Impact of Asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2020;38:1897–1905. PubMed PMC

Baruchel A, Brown P, Rizzari C, et al. . Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open. 2020;5:977. PubMed PMC

Conter V, Bartram CR, Valsecchi MG, et al. . Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206–3214. PubMed

Schrappe M, Valsecchi MG, Bartram CR, et al. . Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077–2084. PubMed

Brigitha L, Fiocco M, Pieters R, et al. . Hypersensitivity to Pegylated E.coli asparaginase as first line treatment in contemporary paediatric acute lymphoblastic leukemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group. Eur J Cancer. 2022;162:65. PubMed

Möricke A, Rizzari C, Alten J, et al. . Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction. HemaSphere. 2023;7:e888. PubMed PMC

Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56:2273–2280. PubMed PMC

Gottschalk Højfeldt S, Grell K, Abrahamsson J, et al. . Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood. 2021;137:2373–2382. PubMed

Kloos RQ, Pieters R, Escherich G, et al. . Allergic-like reactions to Asparaginase: Atypical allergies without Asparaginase inactivation. Pediatr Blood Cancer. 2016;63:1928–1934. PubMed

Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous Asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017;58:540–551. PubMed

Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, et al. . Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-Asparaginase in the induction phase of the AIEOP-BFM A 2009 study. Haematologica. 2019;104:1812–1821. PubMed PMC

Lanvers-Kaminsky C, Rüffer A, Würthwein G, et al. . Therapeutic drug monitoring of asparaginase activity - method comparison of MAAT and AHA test used in the international AIEOP-BFM ALL 2009 Trial. Ther Drug Monit. 2018;40:93–102. PubMed

Würthwein G, Lanvers-Kaminsky C, Gerss J, et al. . Therapeutic drug monitoring of Asparaginase: intra-individual variability and predictivity in children with acute lymphoblastic leukemia treated with PEG-Asparaginasein the AIEOP-BFM ALL 2009 study. Ther Drug Monit. 2020;42:435–444. PubMed

Højfeldt SG, Wolthers BO, Tulstrup M, et al. . Genetic predisposition to PEG-Asparaginase hypersensitivity in children treated according to NOPHO ALL2008. Br J Haematol. 2019;184:405–417. PubMed

Place AE, Stevenson KE, Vrooman LM, et al. . Intravenous pegylated Asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16:1677–1690. PubMed

Jeha S, Pei D, Choi J, et al. . Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16. J Clin Oncol. 2019;37:3377–3391. PubMed PMC

Vora A, Goulden N, Mitchell C, et al. . Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomized controlled trial. Lancet Oncol. 2014;15:809–818. PubMed

Burke MJ, Meenakshi D, Maloney K, et al. . Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on Children’s Oncology Group (COG) clinical trials. Leuk Lymphoma. 2018;59:1624. PubMed PMC